OpGen, Inc. announced that the business combination between Curetis and OpGen has successfully closed on April 1, 2020. At the closing, William E. Rhodes III, the former chairman of the Supervisory Board of Curetis N.V., was appointed chairman of the board of OpGen, and Oliver Schacht, PhD, the former Chief Executive Officer of Curetis N.V., was appointed the President and Chief Executive Officer of OpGen and to the board of directors. In addition to Mr. Rhodes and Mr. Schacht, Mario Crovetto and Prabhavathi Fernandes, former directors of Curetis, were appointed to the OpGen board of directors, such that following the closing the reconstituted board of directors consists of Mr. Rhodes, Mr. Schacht, Mr. Jones.

Mr. Crovetto, Ms. Fernandes, and Don Elsey. The executive officers of OpGen in addition to Chief Executive Officer Oliver Schacht will be Tim Dec, who will continue to serve as Chief Financial Officer and manage the finance and G&A teams globally, and Johannes Bacher, one of Curetis' founders as Chief Operating Officer who will be running global R&D and operations. The Curetis USA Inc. team will be joining OpGen Inc. as employees.

The US commercial team includes Chief Commercial Officer for the Americas, Chris Emery, and Chief Marketing and Scientific Affairs Officer, Faranak Atrzadeh. Andreas Posch, CEO of Ares Genetics GmbH in Vienna, Austria, will also serve on the expanded executive team bringing AI-powered and NGS-based capabilities into the combined business. Evan Jones resigned from his positions as the Company's Chief Executive Officer ("CEO") and Chairman of the Board of Directors of the Company (the "Board"), and (b) Tina Nova, Ph.D. and Misti Ushio, Ph.D. resigned from their position as members of the Board.

Mr. Jones remains as a director of the Company, as does Don Elsey, the chair of the Audit Committee of the Board. Mr. Jones' resignation as CEO of the Company, effective April 1, 2020. In connection with the closing of the Transaction and pursuant to the Implementation Agreement, effective as of April 1, 2020, Mario Crovetto, Prabhavathi Fernandes, Ph.D., William E. Rhodes, III, and Oliver Schacht, Ph.D. were appointed to the Board, in addition to Mr. Jones and R. Donald Elsey, who are remaining on the Board.

Mr. Rhodes will serve as the non-executive Chairman of the Board. Mr. Crovetto served as the chairman of the Audit Committee of Curetis N.V. since its initial public offering ("IPO") in 2015 until April 1, 2020. Dr. Fernandes served as a member of the Curetis N.V. Supervisory Board from 2016 until April 1, 2020.

Until her retirement in December 2016, she was President and CEO and a member of the board of directors of Cempra Pharmaceuticals, a company she founded. Mr. Rhodes served as the chairman of the Supervisory Board of Curetis N.V. since its IPO in 2015 until April 1, 2020. Effective as of April 1, 2020, the Committees of the Board of Directors will consist of: Audit Committee: R. Donald Elsey, Chair, Mario Crovetto and Prabhavathi Fernandes; Compensation Committee: William E. Rhodes, III, Chair., Mario Crovetto and Prabhavathi Fernandes; and Compliance Committee: Evan Jones, Chair, R. Donald Elsey and Prabhavathi Fernandes.